Alexandria Real Estate Equities Stock: Is ARE Underperforming the Real Estate Sector?
Alexandria Real Estate Equities (ARE), a mid-cap life science REIT, reported Q2 2026 adjusted FFO of $1.73 per share, beating estimates, but revenue fell 13% YoY to $662.78M. ARE stock is up 14.3% YTD but down 34.3% over 52 weeks, underperforming the XLRE ETF. Analysts have a 'Hold' consensus rating with a mean price target of $53.
How this was made

The 30-second read
Why it matters
Earnings miss and narrowed guidance suggest near‑term earnings pressure, likely weighing on the stock and sector.
Market read
ARE's earnings shortfall may trigger sector‑wide reassessment of life‑science REIT valuations.
What to watch
Potential upside from upcoming capital transactions and delayed dispositions could improve cash flow later in the year.
Background
ARE is a mid‑cap life‑science REIT with a $9.3 B market cap; Q2 results showed revenue and rental income declines.
Ticker impact
Q2 2026 adjusted FFO of $1.73 per share reported; revenue down 13% YoY; guidance narrowed to $6.35‑$6.45 per share; stock fell 7.8% after release.
Potential further decline of 3‑5% over the next week if guidance holds.
Revenue and rental income fell sharply; guidance below consensus; market reaction already negative.
Market effects
Life‑science REIT sector may see pressure as peers' earnings underperform.
U.S. REIT market could see modest pullback amid weaker real‑estate income data.
Limited to U.S. REIT investors; no broader macro effect.
Counterpoint
If the market overreacts, the dip could present a buying opportunity at a discount.
Key entities
- CompanyAlexandria Real Estate Equities, Inc.
Life‑science REIT reporting Q2 2026 results.


